MedTrace Logo

Minimizing Narcotic Analgesics After Endocrine Surgery

NCT03469310 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2021-05-11

No results posted yet for this study

Summary

This research is being done to better understand and test if the investigators can minimize narcotic medication for controlling pain after thyroid or parathyroid surgery. This research will be performed at Doctors Hospital At Renaissance in the investigators clinic and the perioperative area.

Participants will be randomly chosen to receive one of two options for pain management that the investigators are already using in the care of patients after surgery. One option includes a narcotic medication and one option includes a non-narcotic and a narcotic as needed.

Participants will be asked to complete a form about the level of pain and how much pain medication was needed after surgery in the hospital and while at home. Participants will not have to do any additional visits to participate in this study. The investigators will obtain the research materials at the same time as the usual care visits around the participants' surgery.

Conditions

  • Thyroid Cancer
  • Thyroid Nodule
  • Thyroid Neoplasms
  • Thyroid Goitre
  • Thyroid Diseases
  • Parathyroid Diseases
  • Parathyroid Adenoma
  • Parathyroid Hyperplasia

Interventions

DRUG

Acetaminophen 500Mg Cap

non-narcotic medication first with narcotic as second choice

DRUG

Tylenol #3 Oral Tablet

Narcotic medication first

DRUG

Tramadol

non-narcotic medication first with narcotic as second choice

Sponsors & Collaborators

  • Minerva A Romero Arenas

    lead OTHER

Principal Investigators

  • Minerva A Romero Arenas, MD, MPH · GME General Surgery

  • Samuel K Snyder, MD · GME General Surgery

  • Henry A Reinhart, MD · GME General Surgery

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-09
Primary Completion
2019-12-21
Completion
2020-10-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03469310 on ClinicalTrials.gov